Cargando…
Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer
The aim of this study was to investigate the prognostic significance of lymphocytopenia in advanced‐stage ovarian cancer. We retrospectively reviewed 506 patients with advanced‐stage ovarian cancer at Yonsei Cancer Hospital. This study included two cohorts of patients: a neoadjuvant chemotherapy (NA...
Autores principales: | Lee, Yong Jae, Chung, Young Shin, Lee, Jung‐Yun, Nam, Eun Ji, Kim, Sang Wun, Kim, Sunghoon, Kim, Young Tae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382732/ https://www.ncbi.nlm.nih.gov/pubmed/30652425 http://dx.doi.org/10.1002/cam4.1956 |
Ejemplares similares
-
Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer
por: Kim, Yun-Ji, et al.
Publicado: (2018) -
Role of diagnostic laparoscopy in deciding primary treatment in advanced-stage ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2022) -
Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020) -
Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2018) -
Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)